Skip to main content
OpenTrials
Completed

NCT Number: NCT02021409

Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934

Anaemia is a condition in which blood has a lower than normal number of red blood cells. It can also occur if red blood cells do not contain enough haemoglobin, an oxygen carrying part of blood. Anaemia is common in patients with chronic kidney disease. Healthy kidneys produce a hormone called erythropoietin, which stimulates the bone marrow to produce the proper number of red blood cells needed to carry oxygen to vital organs. Chronic kidney disease is a general term that means that the kidneys are not functioning to their full potential. The study drug, BAY85-3934, is being evaluated as a drug to increase the body's ability to produce erythropoietin.

The purpose of this study is to find out if the study drug, a tablet taken orally, is safe and effective for the treatment of anaemia associated with chronic kidney disease.

The study will enroll 120 patients at multiple locations in Europe, Asia and Australia. Participation will involve a screening visit and between 12 and 15 study visits scheduled over a period of approximately 5 to 7 months. The estimated total duration of study treatment will be 16 weeks. During these scheduled visits patients will undergo a number of procedures to confirm efficacy and safety of the study drug, including measurement of heart rate and blood pressure, physical examination, Electrocardiogram and blood/urine sample collection for laboratory tests.

The study will be conducted at 3 hospitals in the UK. Bayer HealthCare AG is funding this research.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anemia Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hematologic Diseases Hemic and Lymphatic Diseases Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Gosford, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD) at screening
  • Estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73 m2 (Modification of Diet in Renal Disease or the formula according to Matsuo, et al.)
  • Not on dialysis and not expected to begin dialysis during the treatment period of the study (at least 16 weeks from randomization)
  • Treated with darbepoetin via intravenous (IV) or subcutaneous (SC) route with a weekly, bi-weekly, or monthly dose, having had no more than one dose change within 8 weeks prior to randomization
  • At least one kidney
  • Mean screening hemoglobin (Hb) concentration of 10.0 to 12.0 g/dL
  • Men who agree to use adequate contraception when sexually active or women without childbearing potential

Exclusion criteria

  • Subjects with significant acute or chronic bleeding, such as overt gastrointestinal bleeding
  • Active hemolysis or diagnosis of hemolytic syndrome
  • History of myelodysplastic syndrome, multiple myeloma, marrow fibrosis, or pure red-cell aplasia (PRCA)
  • History of hemosiderosis or hemochromatosis
  • Hereditary hemoglobinopathies (such as sickle cell disease and thalassemia major)
  • Aplastic anemia
  • Chronic lymphoproliferative diseases
  • Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy that is likely to require invasive treatment (intraocular injections or laser photocoagulation) during the study
  • Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission
  • Known hypersensitivity to the study drugs (active substances or excipients of the preparations)
  • Uncontrolled and symptomatic hyperparathyroidism
  • Uncontrolled active infection
  • Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively treated > 3 years prior to randomization
  • Any allograft (including renal allograft) in place and on immunosuppressive therapy or a scheduled kidney transplant within the next 16 weeks (being on a waiting list does not exclude the subject)

Treatment and study plan

BAY85-3934

Drug

Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets

darbepoetin alfa

Biological

Primary outcomes

  1. Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period

    Time frame: Baseline and week 12 to 16

Secondary outcomes

  1. Maintenance in hemoglobin target range (10.0 to 12.0 g/dL)

    Time frame: Up to 16 weeks

  2. Change in hemoglobin level

    Time frame: Baseline up to 16 weeks

  3. Number of patients with hemoglobin levels outside the target range

    Time frame: Week 12 to 16

  4. Dose level in the evaluation period

    Time frame: Week 12 to 16

  5. Duration of exposure on each dose level

    Time frame: Up to 16 weeks

  6. Number of subjects requiring titration of dose

    Time frame: Up to 16 weeks

  7. Number of participants with serious adverse events as a measure of safety and tolerability

    Time frame: Up to 16 weeks

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Darbepoetin Alfa) in the Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment in Europe and Asia Pacific

Acronym: DIALOGUE 2

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Dec 27, 2013
Registry last updated
Sep 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.